Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,503 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study.
Urabe F, Muramoto K, Yanagisawa T, Fukuokaya W, Mori K, Tashiro K, Katsumi K, Takahashi H, Yoshihara K, Miyajima K, Imai Y, Iwatani K, Kayano S, Igarashi T, Murakami M, Tsuzuki S, Shimomura T, Yamada H, Miki J, Kimura T; JIKEI‐YAYOI Collaborative Group. Urabe F, et al. Among authors: takahashi h. Int J Urol. 2024 Nov;31(11):1248-1255. doi: 10.1111/iju.15546. Epub 2024 Jul 19. Int J Urol. 2024. PMID: 39031448
Clinical significance of PSA dynamics in castration-sensitive prostate cancer treated with ARSI doublet therapy: A multicenter study.
Urabe F, Hatakeyama S, Yanagisawa T, Narita S, Muramoto K, Katsumi K, Takahashi H, Fukuokaya W, Mori K, Tashiro K, Iwatani K, Shimomura T, Miki J, Habuchi T, Kimura T; JHA Collaborative Group. Urabe F, et al. Among authors: takahashi h. Urol Oncol. 2024 Oct 9:S1078-1439(24)00670-7. doi: 10.1016/j.urolonc.2024.09.028. Online ahead of print. Urol Oncol. 2024. PMID: 39389903
Associations between early changes in the neutrophil-to-lymphocyte ratio after radical nephroureterectomy and treatment outcomes.
Saito S, Takahashi H, Yata Y, Takamizawa S, Hara S, Miyajima K, Iwatani K, Yasue K, Nishikawa H, Yamamoto T, Koide H, Sadakane I, Atsuta M, Mori K, Imai Y, Kayano S, Murakami M, Tashiro K, Tsuzuki S, Yamada H, Miki J, Urabe F, Kimura T, On Behalf Of Jikei-Scrum Collaborative Group. Saito S, et al. Among authors: takahashi h. Jpn J Clin Oncol. 2024 Nov 2;54(11):1201-1207. doi: 10.1093/jjco/hyae081. Jpn J Clin Oncol. 2024. PMID: 38920339
Efficacy of Combined Encorafenib and Binimetinib Treatment for Erdheim-Chester Disease Harboring Concurrent BRAFV600E and KRASG12R Mutations: A Case Report.
Hibino Y, Sakai R, Takahashi H, Takeda T, Hirose N, Tokunaga M, Washimi K, Yokose T, Kasajima R, Hiroshima Y, Miyagi Y, Nakajima H. Hibino Y, et al. Among authors: takahashi h. Cancer Rep (Hoboken). 2024 Dec;7(12):e70093. doi: 10.1002/cnr2.70093. Cancer Rep (Hoboken). 2024. PMID: 39724464 Free PMC article.
Bcl‑xL‑specific BH3 mimetic A‑1331852 suppresses proliferation of fluorouracil‑resistant colorectal cancer cells by inducing apoptosis.
Kato A, Takahashi H, Asai H, Uehara S, Harata S, Fujii Y, Watanabe K, Yanagita T, Suzuki T, Ushigome H, Shiga K, Yamakawa Y, Ogawa R, Mitsui A, Matsuo Y, Takiguchi S. Kato A, et al. Among authors: takahashi h. Oncol Rep. 2025 Feb;53(2):26. doi: 10.3892/or.2024.8859. Epub 2024 Dec 24. Oncol Rep. 2025. PMID: 39717947
14,503 results
You have reached the last available page of results. Please see the User Guide for more information.